8-K: Alumis Reports Q1 2026 Results, Highlights Drug Development Progress

Alumis Inc. announced its first quarter 2026 financial results, reporting a net loss of $93.1 million and highlighting positive Phase 3 data for its psoriasis drug candidate, envudeucitinib.

Summary

• Alumis Inc. reported its financial results for the quarter ended March 31, 2026.
• The company had cash, cash equivalents, and marketable securities totaling $569.5 million as of March 31, 2026.
• Revenue for the quarter was $1.7 million, primarily from collaboration revenue, a decrease from $17.4 million in the prior year's quarter which included license revenue.
• Research and development expenses were $81.5 million, down from $96.6 million in the prior year, due to reduced clinical trial costs.
• General and administrative expenses were $18.6 million, down from $22.3 million, partly due to lower transaction costs from a prior year merger.
• The net loss for the quarter was $93.1 million, an improvement from $99.0 million in the same period last year.
• Phase 3 data for envudeucitinib in plaque psoriasis showed robust PASI responses, with 68.0% achieving PASI 90 by Week 24.
• The company anticipates submitting a New Drug Application (NDA) for envudeucitinib in psoriasis in the fourth quarter of 2026.
• Topline data for a Phase 2b study of envudeucitinib in systemic lupus erythematosus (SLE) is expected in the third quarter of 2026.
• Alumis is exploring strategic alternatives for its lonigutamab program.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report due to strong clinical data for envudeucitinib and a solid cash runway, despite a significant year-over-year revenue decrease which was anticipated.

Positives

• Late-breaking Phase 3 data for envudeucitinib in moderate-to-severe plaque psoriasis demonstrated early and robust improvements in skin clearance and quality of life.
• PASI 90 responses reached 68.0% and PASI 100 responses reached 41.0% by Week 24 in Phase 3 trials.
• Envudeucitinib showed early onset of action with quality-of-life improvements and itch relief emerging ahead of skin clearance.
• Clear or almost clear scalp psoriasis was observed in approximately three out of four patients by Week 24.
• Envudeucitinib demonstrated a favorable safety and tolerability profile consistent with prior studies.
• The company remains on track for its NDA submission for envudeucitinib in psoriasis in Q4 2026.
• Potentially pivotal Phase 2b topline data for envudeucitinib in SLE is anticipated in Q3 2026.
• The company's cash, cash equivalents, and marketable securities of $569.5 million are expected to fund operations into Q4 2027.

Negatives

• Revenue decreased significantly to $1.7 million in Q1 2026 from $17.4 million in Q1 2025, primarily due to the absence of license revenue from a prior year agreement.
• The company reported a net loss of $93.1 million for the quarter.
• Alumis has decided to explore strategic alternatives for its lonigutamab program, indicating a potential divestiture or discontinuation.

Risks

• The company's drug candidates, including envudeucitinib, are subject to the risks and uncertainties of clinical trials, regulatory approval, and commercialization.
• There is a risk that actual results could differ materially from forward-looking statements due to various factors, including the timing and results of clinical trials.
• Alumis's ability to fund its development activities and achieve its development goals is subject to market conditions and regulatory outcomes.
• The company faces risks related to protecting its intellectual property.

Future Outlook

Alumis anticipates submitting its NDA for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of 2026. Topline data from the potentially pivotal Phase 2b study in systemic lupus erythematosus (SLE) is expected in the third quarter of 2026. The company also expects an update on its unified TYK2 franchise development strategy, including evaluation of additional indications, in the second quarter of 2026. A first-in-class Phase 1 trial for its next clinical candidate is anticipated in the second half of 2026. The company's current cash position is expected to fund operations into the fourth quarter of 2027.

Management Comments

• "Alumis delivered a focused and productive first quarter, building on the Phase 3 clinical validation of envudeucitinib in moderate-to-severe plaque psoriasis and reinforcing the differentiated potential of maximal TYK2 inhibition."
• "Late-breaking Phase 3 data at the 2026 American Academy of Dermatology Annual Meeting demonstrated leading skin-clearance outcomes and meaningful improvements in patient-reported quality-of-life measures, supporting a compelling emerging profile for physicians and patients, if approved, and further strengthening our confidence in envudeucitinibs potential to reshape the psoriasis treatment landscape."
• "We remain on track for our NDA submission in the fourth quarter of this year, as well as the potentially pivotal LUMUS Phase 2b topline readout in SLE in the third quarter."
• "With continued progress across both indications, envudeucitinib is emerging as a potential pipeline in a pill, supporting expansion into additional immune-mediated diseases. We are evaluating further indications under a unified TYK2 franchise strategy and expect to share further updates later this year."

Industry Context

StockSavvy.ai notes that Alumis's progress with envudeucitinib aligns with the broader biopharmaceutical industry trend of developing targeted oral therapies for immune-mediated diseases, aiming to offer more convenient and potentially safer alternatives to injectable biologics. The focus on TYK2 inhibition is a key area of research for conditions like psoriasis and lupus.

Comparison to Industry Standards

• The PASI 90 response rate of 68.0% and PASI 100 response rate of 41.0% for envudeucitinib in Phase 3 plaque psoriasis trials are competitive with other leading oral and injectable therapies in the moderate-to-severe psoriasis market. For example, other approved TYK2 inhibitors and IL-17 inhibitors have demonstrated similar or higher response rates in their respective pivotal trials, though direct comparisons require careful consideration of trial design and patient populations.
• The company's cash runway extending into Q4 2027 is a positive indicator, providing sufficient time for clinical development and regulatory submissions, which is crucial in the capital-intensive biopharmaceutical sector. Many clinical-stage biotechs aim for a similar or longer runway to de-risk development.

Stakeholder Impact

• Shareholders: Positive impact from strong clinical data and extended cash runway, potentially increasing the value of their investment. Negative impact from the significant revenue decrease and continued net loss.
• Patients: Potential future benefit from a new oral therapy for psoriasis and lupus, offering improved treatment options.
• Employees: Continued employment and potential growth opportunities as the company advances its pipeline.

Next Steps

• Submit NDA for envudeucitinib in moderate-to-severe plaque psoriasis (4Q 2026).
• Report topline data for Phase 2b SLE study of envudeucitinib (3Q 2026).
• Provide update on unified TYK2 franchise development strategy and evaluation of additional indications (2Q 2026).
• Initiate Phase 1 trial for next clinical candidate (2H 2026).
• Report long-term data from ONWARD3 and two-year safety data from Phase 2 study (2H 2026).
• Explore strategic alternatives for the lonigutamab program.

Key Dates

Recommendation

The strong clinical data for envudeucitinib and extended cash runway are positive, supporting a 'hold' recommendation. However, the significant revenue decline and continued net loss, coupled with the need for regulatory approvals and market adoption, warrant a cautious approach. Further de-risking events, such as NDA approval and successful market entry, would be needed to justify a stronger 'buy' rating.

Keywords

Alumis Inc., envudeucitinib, plaque psoriasis, systemic lupus erythematosus, TYK2 inhibitor, Phase 3 trial, NDA submission, biopharmaceutical